Loading...
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
In the latest years, some drugs have been approved by European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) for the treatment of patients with advanced non-small cell lung cancer (NSCLC), particularly for the treatment of those who have no targeted gene mutations or who ha...
Na minha lista:
| Udgivet i: | Cancer Manag Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699593/ https://ncbi.nlm.nih.gov/pubmed/31616186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212238 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|